Tizona Therapeutics, Inc.

AbbVie Inc. has returned its rights to a MerTK inhibitor program licensed from originator Dong-A ST well over four years ago, marking a setback for the leading South Korean pharma firm’s plan to step

Gilead Sciences, Inc. entered into partnership negotiations with Immunomedics, Inc. six months ago and emerged from those discussions on 13 September with plans to buy the company for $21bn, giving

Who: Gilead Sciences/Jounce Therapeutics What: In its sixth major cancer deal of 2020, Gilead will license a preclinical immuno-oncology agent from Jounce that is thought to offer potential in both

Gilead Sciences, Inc. is likely to spend a lot of its second quarter earnings call talking about remdesivir, the company’s antiviral drug endorsed in the US and EU for the treatment of hospitalized C